Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Mee...
May 20 2019 - 8:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) targeting cancers in
areas of high unmet medical need, today announced that it will
present interim data from the ongoing Phase 1 dose-escalation study
evaluating XMT-1536, its first-in-class ADC candidate targeting
NaPi2b, in patients with ovarian cancer, non-small cell lung
(NSCLC) adenocarcinoma and other rare tumor types. The data will be
presented in a poster session and poster discussion at the
2019 American Society of Clinical Oncology (ASCO) Annual
Meeting being held from May 31 – June 4, 2019 in Chicago, IL.
Details of the poster display and discussion are
as follows:
Poster Title: Phase 1 dose
escalation study of XMT-1536, a novel NaPi2b-targeting
antibody-drug conjugate (ADC), in patients (pts) with solid tumors
likely to express NaPi2b.Abstract Number:
3010Date: June 1, 2019Poster
Display: 8:00 AM – 11:00 AM C.T., Location – Hall A,
Poster Board #2Poster Discussion: 3:00 PM – 3:22
PM C.T., Location – E450Session: Developmental
Therapeutics and Tumor Biology (Nonimmuno)
About Mersana
TherapeuticsMersana Therapeutics is a clinical-stage
biopharmaceutical company using its differentiated and proprietary
ADC platforms and its modular Synthemer scaffold to develop highly
targeted drugs with increased tolerability and expanded
opportunities to deliver meaningful clinical benefit to patients.
Mersana’s lead product candidate, XMT-1536, is in a Phase 1
clinical trial in patients with tumors expressing NaPi2b, including
ovarian cancer, NSCLC adenocarcinoma, and other cancers. In
addition, multiple partners are using Mersana’s platform to advance
their ADC pipelines.
Contact:
Investor ContactSarah Carmody,
617-844-8577scarmody@mersana.com
Media ContactPaul Kidwell,
617-680-1088pkidwell@mersana.com
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Apr 2023 to Apr 2024